Sanofi And Regeneron Add Four New Dupixent-Style Antibodies

Sanofi and Regeneron have expanded their immunology partnership with a $1 billion deal. The agreement aims to advance therapies in the immunology field, benefiting both companies' pipelines and potentially boosting their market positions.

Sanofi (SASY) shares rose 1.4% to €73.65 after announcing an $8B collaboration with Regeneron to co-develop and co-commercialize four new antibodies. The deal includes a $1B upfront payment and up to $7B in milestone payments. Analysts have a Buy rating and a 12-month price target of €94.06, suggesting significant upside from current levels.

Sanofi will pay Regeneron $1B upfront and up to $7B in milestones for four new antibodies under their Dupixent partnership. Sanofi shares rose 2% on the news. The deal aims to strengthen Sanofi's pipeline before Dupixent's patent expiry. Regeneron will lead R&D, while Sanofi handles global sales. Profits and costs will be split equally, with existing Dupixent terms unchanged.

Sanofi and Regeneron expanded their collaboration with an $80B deal, including a $10B upfront payment. They will develop four new antibody therapies for inflammatory diseases. Regeneron will handle development, while Sanofi manages global sales. Regeneron's stock is considered 16.4% undervalued with a GF Score of 88/100, indicating strong financial health and growth potential.

Regeneron's experimental weight-loss drug, combined with Novo Nordisk's semaglutide, reduced muscle mass loss by 50% in a study. The trial involved patients using both drugs.

Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance, targeting type 2 inflammation with four antibodies. Regeneron will receive $1B upfront and up to $7B in milestones. They will share development costs and profits equally. The deal builds on their 20-year collaboration, including Dupixent, used by 1.5M patients.